Feb 06
BSE+NSE Vol: 89.03 k
News and Views
2 Feb: Stock opens strong at Rs.1,905.75 (+1.62%) despite Sensex decline
4 Feb: Q3 FY26 results highlight strong momentum amid valuation concerns
5 Feb: Intraday high of Rs.1,999 with a 7.06% surge, outperforming Sensex
6 Feb: Technical momentum shifts to mildly bullish with 4.00% gain; valuation turns very expensive
Metropolis Healthcare Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underscored by a 4.00% gain in the stock price on 6 Feb 2026, closing at ₹1,966.85, up from the previous close of ₹1,891.25. Despite mixed signals from key technical indicators, the stock’s recent performance suggests cautious optimism among investors in the healthcare services sector.
Read full news article
Metropolis Healthcare Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive category, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change prompts a reassessment of the stock’s price attractiveness, especially when compared to its historical averages and peer group metrics within the healthcare services sector.
Read full news articleMetropolis Healthcare Ltd's latest financial results for Q2 FY26 indicate a company experiencing significant revenue growth alongside some challenges in profitability metrics. The company reported net sales of ₹429.19 crores, reflecting a year-on-year growth of 22.70%, which marks a notable acceleration compared to the previous fiscal year. This growth is supported by an increase in healthcare awareness and demand for diagnostic services. Net profit for the quarter reached ₹52.67 crores, representing a year-on-year increase of 13.22% and a sequential improvement of 16.89%. This profit level is the highest recorded in the trailing twelve months, indicating effective operational leverage despite some pressure on margins. The profit after tax (PAT) margin expanded to 12.32% from the previous quarter's 11.72%, although it remains below the 13.35% achieved in the same quarter last year. However, the operating ...
Read full news article
Metropolis Healthcare Ltd demonstrated robust intraday performance on 5 Feb 2026, surging to an intraday high of Rs 1,999, marking a 7.06% increase from its previous close. This rally outpaced the broader Healthcare Services sector by 6.12% amid a generally subdued market environment.
Read full news articleMetropolis Healthcare Ltd's latest financial results for the quarter ending September 2025 reflect a continuation of its growth trajectory, with both revenue and net profit showing positive trends. The company reported consolidated net sales of ₹429.19 crores, which represents a year-on-year growth of 22.70%. This robust revenue growth indicates strong underlying demand for its diagnostic services, supported by both organic expansion and contributions from network initiatives. Net profit for the same period stood at ₹52.67 crores, marking a year-on-year increase of 13.22%. The operating margin improved to 25.22%, up from 23.25% in the previous quarter, highlighting effective cost management and operational efficiency. This margin expansion is particularly noteworthy as it approaches the company's historical peak, suggesting that Metropolis Healthcare is successfully navigating its expansion phase while mai...
Read full news article
Metropolis Healthcare Ltd., a leading diagnostic services provider with a market capitalisation of ₹9,741 crores, delivered a robust performance in Q2 FY26 (July-September 2025), with consolidated net profit surging 13.22% year-on-year to ₹52.67 crores. The stock, trading at ₹1,891.25, has declined 0.47% following the results announcement, reflecting investor concerns about premium valuations despite strong operational momentum.
Read full news article
Metropolis Healthcare Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 11 August 2025. While this rating change occurred several months ago, the analysis and financial metrics discussed here reflect the company’s current position as of 31 January 2026, providing investors with an up-to-date perspective on the stock’s fundamentals and market performance.
Read full news article
Recent Price Movement and Market Performance
Metropolis Healthcare’s stock has been on a downward trajectory over the past week, losing 5.90% compared to the Sensex’s more modest decline of 2.43%. This underperformance extends over the last month and year-to-date periods, with the stock falling 5.79% and 7.06% respectively, while the Sensex declined by 4.66% and 4.32% in the same intervals. Even over a one-year horizon, the stock has declined by 3.89%, contrasting with the Sensex’s 6.56% gain. These figures highlight a persistent weakness in the stock’s price action relative to the broader market.
On the day in question, the stock underperformed its sector by 4.13%, touching an intraday low of ₹1,792.40, down 4.88%. Notably, the stock has been falling for two consecuti...
Read full news articleAnnouncementNewspaper advertisement
Postal Ballot Notice for Issue of Bonus Shares
Link of audio recording of the earnings conference call held on February 05 2026
Corporate Actions
No Upcoming Board Meetings
Metropolis Healthcare Ltd has declared 200% dividend, ex-date: 11 Nov 25
No Splits history available
No Bonus history available
No Rights history available
